24 completed, 2 active not recruiting, 2 terminated, 1 recruiting. 18 Phase 1, 10 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 15, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 10 | Completed 8, Active not recruiting 1, Terminated 1 |
| Not applicable | 1 | Withdrawn 1 |
Follow Recurrent Childhood Ependymoma: new trials by email Literature Review of Recurrent Childhood Ependymoma trials Research Report on Recurrent Childhood Ependymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling Functional Precision Medicine - Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Florida International University | 65 | 2023-02-22 | 2026-08-26 |
| Ex Vivo Drug Sensitivity Testing and Mutation Profiling Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia | Completed | Florida International University | 25 | 2019-02-21 | 2023-05-10 | |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-10-16 |
| Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors Everolimus, Laboratory Biomarker Analysis, Pharmacological Study - CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 22 | 2018-01-13 | 2021-08-27 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors Intra thecal methotrexate, topotecan, cyclophosphamide - Recurrent Childhood Medulloblastoma, Recurrent Childhood Ependymoma | Phase 2 | Terminated | Nicklaus Children's Hospital f/k/a Miami Children's Hospital | 3 | 2016-02-01 | 2020-01-10 |
| Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging - Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 71 | 2015-06-03 | 2026-07-20 |
| Everolimus for Children With Recurrent or Progressive Ependymoma Everolimus - Recurrent Childhood Ependymoma | Phase 2 | Completed | University of Texas Southwestern Medical Center | 11 | 2015-02-01 | 2024-05-08 |
| Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors gallium Ga 68-edotreotide, positron emission tomography, computed tomography - Acoustic Schwannoma, Adult Anaplastic Astrocytoma | Not applicable | Withdrawn | Sue O'Dorisio | 2013-09-01 | 2017-04-28 | |
| Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Sunitinib Malate - Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2012-01-01 | 2015-08-27 |
| Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 129 | 2010-03-01 | 2014-11-05 |
| Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors vorinostat, temozolomide, diagnostic laboratory biomarker analysis - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-02-01 | 2013-05-03 |
| Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma vorinostat, bortezomib, pharmacological study - Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2009-08-01 | 2013-07-02 |
| ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors veliparib, temozolomide, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 31 | 2009-07-01 | 2014-07-09 |
| Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor busulfan, melphalan, topotecan hydrochloride - Solid Tumor, Adult Central Nervous System Germ Cell Tumor | Phase 1 | Completed | City of Hope Medical Center | 25 | 2007-02-26 | 2025-03-20 |
| Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Bevacizumab, Fludeoxyglucose F-18, Irinotecan Hydrochloride - Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma | Phase 2 | Completed | National Cancer Institute (NCI) | 97 | 2006-08-01 | 2017-11-28 |
| Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma ispinesib, laboratory biomarker analysis, pharmacological study - Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2006-06-01 | 2013-01-16 |
| AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Cediranib Maleate - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 55 | 2006-03-01 | 2016-03-07 |
| Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas irinotecan hydrochloride, oxaliplatin - Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2005-03-01 | 2013-06-05 |
Showing 20 of 30. Sign in to see all of them.
Familial ependymoma (30) · Medulloblastoma (25) · Astrocytoma (20) · Optic Nerve Glioma (17) · Oligodendroglioma (14) · Choroid Plexus Neoplasms (12) · Rhabdoid Tumor (11) · Neuroblastoma (9) · Ependymoma (8) · Neuroectodermal Tumors, Primitive, Peripheral (8) · Dendritic Cell Sarcoma, Interdigitating (7) · Osteosarcoma (7) · Spinal Cord Neoplasms (7) · Glioma (6) · Wilms Tumor (6)
Neoplasms by Histologic Type (30) · Neoplasms (29) · Neoplasms, Germ Cell and Embryonal (28) · Neoplasms, Glandular and Epithelial (28) · Neoplasms, Nerve Tissue (28) · Neuroectodermal Tumors (28) · Neoplasms, Neuroepithelial (27) · Neoplasms by Site (24) · Neuroectodermal Tumors, Primitive (24) · Nervous System Diseases (23) · Nervous System Neoplasms (23) · Glioma (22) · Central Nervous System Neoplasms (18) · Central Nervous System Diseases (17) · Cranial Nerve Diseases (17)
Magnetic Resonance Spectroscopy (4) · Temozolomide (4) · Irinotecan (3) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (2) · Everolimus (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Oxaliplatin (2) · Specimen Handling (2) · Topotecan (2) · Vorinostat (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Bevacizumab (1) · Biopsy (1) · Bone Marrow Transplantation (1)
National Cancer Institute (NCI) (21) · Children's Oncology Group (2) · Florida International University (2) · City of Hope Medical Center (1) · Nicklaus Children's Hospital f/k/a Miami Children's Hospital (1) · Pediatric Brain Tumor Consortium (1) · Sue O'Dorisio (1) · University of Texas Southwestern Medical Center (1)
United States (30) · Canada (5) · Puerto Rico (4) · Australia (2) · New Zealand (1) · Switzerland (1)
Maryam Fouladi (2) · Alice Lee (1) · Amar Gajjar (1) · Anna Pawlowska, MD (1) · Cynthia Wetmore (1) · Daniel C Bowers, MD (1) · Daria Salyakina, PhD (1) · Diana Azzam (1) · Diana Azzam, PhD (1) · Eugene I Hwang (1) · Jack Su (1) · James Whitlock (1) · Jodi Muscal (1) · Julia Glade-Bender (1) · Katherine Warren (1)
PMID 31401903, PMID 18447671, PMID 23554030, PMID 27109549, PMID 32623479, PMID 33852135, PMID 34738048, PMID 36950217, PMID 38605166, PMID 38815151, PMID 39298716
U01CA097452 (8), U01CA081457 (7), U10CA098543 (4), U10CA180886 (3), UM1CA081457 (3), P30CA086862 (1), U54MD012393 (1), UG1CA189958 (1)